Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
Growing incidence rate, rapid technological advancements in diagnostic methods, better access to healthcare, and rising awareness about GBM are among the major factors contributing to the growth of this market in the U.S. According to American Association of Neurological Surgeons, the incidence of GBM is 3/100,000 people per year in the country.
As per National Brain Tumor Society, GBM is recorded in more than 48% of primary malignant brain tumors, and around 10,000 Americans are diagnosed with GBM each year. The incidence of GBM is growing rapidly with increasing geriatric population and advancements in diagnostic & treatment methods.
High investments in R&D of rare diseases and supportive government policies have fueled development activities of novel GBM therapies, which is expected to propel the market growth in the coming years.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account